SEARCH

SEARCH BY CITATION

References

  • 1
    Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. HEPATOLOGY 2002; 35: 746752.
  • 2
    Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. HEPATOLOGY 2005; 41: 11511159.
  • 3
    McCullough AJ. The epidemiology and risk factors of NASH. In: FarrellGC, GeorgeJ, HallP, McCulloughAJ, eds. Fatty liver disease: NASH and related disorders. Oxford: Blackwell Publishing; 2005: 2337.
  • 4
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 14131419.
  • 5
    Ong JP, Younossi ZM. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin Liver Dis 2005; 9: 617634, vi.
  • 6
    Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005; 330: 326335.
  • 7
    Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310315.
  • 8
    Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005; 23: 3646.
  • 9
    Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 2005; 23: 36143621.
  • 10
    Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd. Technology insight: pharmacoproteomics for cancer–promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 2006; 3: 256268.
  • 11
    Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 2004; 40: 26232632.
  • 12
    Baranova A, Schlauch K, Gowder S, Collantes R, Chandhoke V, Younossi ZM. Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver Int 2005; 25: 10911096.
  • 13
    Oveland E, Fladmark KE, Wergeland L, Gjertsen BT, Hovland R. Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. Curr Pharm Biotechnol 2006; 7: 185198.
  • 14
    Ron D, Jurd R. The “ups and downs” of signaling cascades in addiction. Sci STKE 2005; 2005: re14.
  • 15
    Kholodenko BN, Demin OV, Moehren G, Hoek JB. Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 1999; 274: 3016930181.
  • 16
    Mandell JW. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003; 163: 16871698.
  • 17
    Blaydes JP, Vojtesek B, Bloomberg GB, Hupp TR. The development and use of phospho-specific antibodies to study protein phosphorylation. Methods Mol Biol 2000; 99: 177189.
  • 18
    Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3: 20852090.
  • 19
    Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 2006; 6: 146155.
  • 20
    Speer R, Wulfkuhle JD, Liotta LA, Petricoin EF 3rd. Reverse-phase protein microarrays for tissue-based analysis. Curr Opin Mol Ther 2005; 7: 240245.
  • 21
    Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003; 3: 317325.
  • 22
    Biener-Ramanujan E, Ramanujan VK, Herman B, Gertler A. Spatio-temporal kinetics of growth hormone receptor signaling in single cells using FRET microscopy. Growth Horm IGF Res 2006; 16: 247257.
  • 23
    Ho AK, Price DM, Terriff D, Chik CL. Timing of mitogen-activated protein kinase (MAPK) activation in the rat pineal gland. Mol Cell Endocrinol 2006; 252: 3439.
  • 24
    Pe'er D. Bayesian network analysis of signaling networks: a primer. Sci STKE. 2005; 2005: pl4.
  • 25
    Li Z, Chan C. Inferring pathways and networks with a Bayesian framework. FASEB J 2004; 18: 746748.
  • 26
    Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, de Freitas LA, Barreto D, et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 2005; 17: 837841.
  • 27
    Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 18981906.
  • 28
    Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147152.
  • 29
    Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nut. 2006; 83: 461S465S.
  • 30
    Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347355.
  • 31
    Huang D, Cheung AT, Parsons JT, Bryer-Ash M. Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes. Biol Chem 2002; 277: 1815119160.
  • 32
    Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell Signal 2006; 18: 401408.
  • 33
    Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005; 280: 27372744.
  • 34
    Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 29172921.
  • 35
    Baranova A, Gowder SJ, Schlauch K, Elariny H, Collantes R, Afendy A, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg 2006; 16: 11181125.
  • 36
    Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006; 4: 10481052.
  • 37
    Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, et al. Metabolic and adipokine profile of chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 11541161.
  • 38
    Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279: 3081730822.
  • 39
    Zhang X, Gan L, Pan H, Guo S, He X, Olson ST, et al. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms: direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 2002; 277: 4527645284.
  • 40
    Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 2005; 54: 20032011.